Literature DB >> 4034850

Differential responses in prolactin levels induced by naloxone in humans.

L Steardo, P Monteleone, C A Tamminga, P L Canonico, D Denman, U Scapagnini, T N Chase.   

Abstract

The plasma prolactin (PRL) response to the opiate antagonist naloxone was tested in drug-free healthy volunteers (10 men, 18 regularly menstruating women who were in the late follicular phase of their ovarian cycles, and seven post-menopausal women). Naloxone hydrochloride (2 mg intravenous bolus) and placebo (normal saline) were administered on two different days in a double-blind fashion. Blood samples were collected at -15, 0, 30, 60, 120, 180 and 240 min after the injection. In the women of reproductive age, naloxone reduced plasma PRL concentrations, whereas in the post-menopausal women and the men, naloxone resulted in no significant change. However, in the post-menopausal women treated with estrogen (intramuscular 17-beta-estradiol), the opiate antagonist was able to lower plasma PRL concentrations. Thus, it appears that opiate effects on PRL secretion are influenced by the gonadal steroid environment and that estrogens may play a modulating role.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4034850     DOI: 10.1016/0306-4530(85)90058-7

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  3 in total

1.  Gonadal steroids do not affect basal growth hormone response to naloxone in humans.

Authors:  P Monteleone; M Maj; M Iovino; L Fiorenza; P M Fiumani; L Steardo
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

Review 2.  The effects of opioids and opioid analogs on animal and human endocrine systems.

Authors:  Cassidy Vuong; Stan H M Van Uum; Laura E O'Dell; Kabirullah Lutfy; Theodore C Friedman
Journal:  Endocr Rev       Date:  2009-11-10       Impact factor: 19.871

Review 3.  Medical and psychological risks and consequences of long-term opioid therapy in women.

Authors:  Beth D Darnall; Brett R Stacey; Roger Chou
Journal:  Pain Med       Date:  2012-08-20       Impact factor: 3.750

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.